Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock

The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock

Published October 5, 2026 · Category: Finance

Overview

Eli Lilly (NYSE:LLY) is the only healthcare stock in the trillion-dollar club, and for good reason. Its business has been booming due to its successful GLP-1 drugs, Mounjaro and Zepbound. They are highly effective and are dominating the market.

However, with the stock rallying roughly 400% in the past five years, its valuation has become a bit rich. Although it may still look like a tenable investment given its future growth opportunities, its continued dominance in the GLP-1 market is by no means a sure thing. Here's what investors need to know about the healthcare stock before investing in it.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.